The recent position articulated by the Malaysian Medical Association (MMA) brings to the surface a long-standing and increasingly visible tension within our health care system – the balance between preserving clinical autonomy and ensuring financial sustainability.
At its core, the principle that clinical decisions must be made by qualified medical professionals, based on patient needs and sound medical judgement, is unquestionable. This is the foundation of trust in health care. Any perception that non-clinical entities are overriding or unduly influencing such decisions naturally raises concern among providers and patients alike.
However, it is equally important to situate this discussion within the broader realities of today’s health care landscape. Malaysia, like many other countries, is experiencing sustained medical inflation, increasing chronic disease burden, and higher utilisation driven by both awareness and accessibility.
In such an environment, third-party administrators (TPAs) and insurers are not merely administrative intermediaries, but financial stewards tasked with ensuring that health care coverage remains sustainably viable for employers, individuals, and the system as a whole.
Without some form of utilisation management, cost optimisation, and benefit structuring, the risk is clear and resulting in premiums escalate, employers reduce coverage, and eventually access becomes more limited for the very patients we aim to protect.
This is where the perceived conflict emerges. From the provider’s standpoint, any limitation, whether in the form of formularies, panel restrictions, pre-authorisation, or cost caps may be seen as an intrusion into clinical independence.
From the payor’s standpoint, these mechanisms are necessary tools to prevent overutilisation, manage moral hazard, and maintain affordability at scale. The reality is that both positions are grounded in legitimate concerns, but the system today often lacks the alignment mechanisms to reconcile them effectively.
A key issue is that many existing controls are implemented in a relatively blunt or static manner, which can unintentionally create frictions. For example, rigid benefit limits or non-dynamic approval processes may not adequately account for patient complexity, clinical nuance, or evolving standards of care.
This can lead to situations where doctors feel constrained, patients feel caught in between, and payors are perceived as gatekeepers rather than enablers. At the same time, the absence of any controls is not a viable alternative either, as it risks driving unsustainable cost escalation and potential abuse within the system.
What is needed, therefore, is not the removal of either clinical authority or financial governance, but a more intelligent integration of both. This begins with greater transparency ensuring that clinical guidelines, coverage policies, and decision criteria are clearly communicated and grounded in evidence-based medicine.
It also requires the use of better data and technology to enable more dynamic and context-aware decision-making, rather than one-size-fits-all restrictions. For instance, real-time insights into patient history, smart care pathway, treatment outcomes, and cost benchmarks can support both doctors and payors in making more informed, aligned decisions.
Equally important is the alignment of incentives. Today, different stakeholders in health care are often driven by different metrics. For instance, providers are driven by clinical outcomes and service delivery, payors by cost management, and patients by access and convenience.
Without a shared framework that connects these objectives, friction is inevitable. Moving towards value-based models, where quality, outcomes, costs and efficiency are jointly rewarded, may help bridge this divide over time.
From the patient’s perspective, which must ultimately remain central, the expectation is not to navigate these tensions, but to receive care that is appropriate, timely, and affordable.
Patients should not feel that their care is compromised by cost considerations, nor should they be exposed to unnecessary treatments driven by system inefficiencies.
Achieving this balance requires trust, the trust that doctors will act in their best interest, and trust that the system will support, rather than hinder, appropriate care. And trust requires time, transparency and accountability.
In this context, the current discourse should not be framed as a zero-sum debate between doctors and corporate schemes, but as an opportunity to evolve the system towards better coordination.
Clinical autonomy must be respected and safeguarded, but it should be complemented by data-driven insights, collaborative frameworks, and sustainable financing models.
Likewise, TPAs and insurers should continue to play their role, but with greater sensitivity to clinical realities and a stronger emphasis on enabling, rather than restricting, appropriate care pathways.
Ultimately, protecting clinical judgement and ensuring system sustainability are not opposing goals. They are interdependent responsibilities. A health care system that fully respects one while neglecting the other will struggle to deliver long-term value.
The way forward lies in building a more integrated ecosystem where doctors, payors, and patients are aligned around a common objective, and that is delivering the right care, at the right time, at the right cost, without compromising trust and outcomes.
Dr Raymond Choy is founder and CEO of Heydoc Health, as well as secretary of the Association of Digital Health Malaysia.
- This is the personal opinion of the writer or publication and does not necessarily represent the views of CodeBlue.
